Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Kronbichler, Andreas ^a   Saleem, Moin A ^b   Meijers, Björn ^c   Shin, Jae Il ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; UROKINASE RECEPTOR; BIOLOGICAL MARKER; LIGAND; PROTEIN BINDING; UROKINASE;

FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PODOCYTE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; DISEASE MODEL; DISEASE PREDISPOSITION; GENETICS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOMODULATION; METABOLISM;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOMODULATION; INTEGRINS; LIGANDS; PODOCYTES; PROTEIN BINDING; PROTEINURIA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84982804444     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/2068691     Document Type: Review

References (106)

1. A. B. Fogo, "Causes and pathogenesis of focal segmental glomerulosclerosis, " Nature Reviews Nephrology, vol. 11, no. 2, pp. 76-87, 2015.
2. B. Bose and D. Cattran, "Glomerular diseases: FSGS, " Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 626-632, 2014.
3. W. Y. Ding, A. Koziell, H. J. McCarthy et al., "Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence, " Journal of the American Society of Nephrology, vol. 25, no. 6, pp. 1342-1348, 2014.
4. J. A. Jefferson and S. J. Shankland, "The pathogenesis of focal segmental glomerulosclerosis, "Advances in Chronic KidneyDisease, vol. 21, no. 5, pp. 408-416, 2014.
5. S. M. L. deMik, M. J. Hoogduijn, R. W. de Bruin, and F. J. M. F. Dor, "Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models, "BMC Nephrology, vol. 14, article 74, 2013.
6. C. Schell and T. B. Huber, "New players in the pathogenesis of focal segmental glomerulosclerosis, " Nephrology Dialysis Transplantation, vol. 27, no. 9, pp. 3406-3412, 2012.
7. E. T. McCarthy, M. Sharma, and V. J. Savin, "Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 2115-2121, 2010.
8. J. Reiser, C. C. Nast, and N. Alachkar, "Permeability factors in focal and segmental glomerulosclerosis, " Advances in Chronic Kidney Disease, vol. 21, no. 5, pp. 417-421, 2014.
9. C. Wei, S. ElHindi, J. Li et al., "Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis, " Nature Medicine, vol. 17, no. 8, pp. 952-960, 2011.
10. C. Wei, H. Trachtman, J. Li et al., "Circulating suPAR in two cohorts of primary FSGS, " Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 2051-2059, 2012.
11. G. Cara-Fuentes, C. Wei, A. Segarra et al., "CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance, " Pediatric Nephrology, vol. 29, no. 8, pp. 1363-1371, 2014.
12. J. Huang, G. Liu, Y.-M. Zhang et al., "Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis, " Kidney International, vol. 84, no. 2, pp. 366-372, 2013.
13. F. Li, C. Zheng, Y. Zhong et al., "Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS, " Clinical Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 1903-1911, 2014.
14. R. J. H. Maas, J. F. M. Wetzels, and J. K. J. Deegens, "Serumsoluble urokinase receptor concentration in primary FSGS, " Kidney International, vol. 81, no. 10, pp. 1043-1044, 2012.
15. M. E. Bock, H. E. Price, L. Gallon, and C. B. Langman, "Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report, " Clinical Journal of the American Society of Nephrology, vol. 8, no. 8, pp. 1304-1311, 2013.
16. B. Meijers, R. J. H. Maas, B. Sprangers et al., "The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis, " Kidney International, vol. 85, no. 3, pp. 636-640, 2014.
17. T. Wada, M. Nangaku, S. Maruyama et al., "A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease, " Kidney International, vol. 85, no. 3, pp. 641-648, 2014.
18. A. Sinha, J. Bajpai, S. Saini et al., "Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children, " Kidney International, vol. 85, no. 3, pp. 649-658, 2014.
19. A. Segarra, E. Jatem, M. T. Quiles et al., "Diagnostic value of soluble urokinase receptor serum levels in adults with idiopathic nephrotic syndrome, " Nefrologia, vol. 34, no. 1, pp. 46-52, 2014.
20. Y. Harita, K. Ishizuka, A. Tanego et al., "Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis, " Pediatric Nephrology, vol. 29, no. 9, pp. 1553-1560, 2014.
21. C. Musetti, M. Quaglia, T. Cena et al., "Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis, " Journal of Nephrology, vol. 28, no. 3, pp. 299-305, 2015.
22. C. R. Franco Palacios, J. C. Lieske, H. M. Wadei et al., "Urine but not serumsoluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates, " Transplantation, vol. 96, no. 4, pp. 394-399, 2013.
23. J. M. Spinale, L. H. Mariani, S. Kapoor et al., "A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease, " Kidney International, vol. 87, no. 3, pp. 564-574, 2015.
24. Y. Taniguchi, Y. Shimamura, T. Horino, S. Fujimoto, and Y. Terada, "Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease, " Kidney International, vol. 86, no. 1, pp. 209-210, 2014.
25. J. R. Hoyer, L. Raij, R. Vernier, R. Simmons, J. Najarian, and A. Michael, "Recurrence of idiopathic nephrotic syndrome after renal transplantation, " The Lancet, vol. 300, no. 7773, pp. 343-348, 1972.
26. M. Vinai, P. Waber, and M. G. Seikaly, "Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review, " Pediatric Transplantation, vol. 14, no. 3, pp. 314-325, 2010.
27. R. J. H. Maas, J. K. J. Deegens, J. A. J. G. van den Brand, E. A. M. Cornelissen, and J. F. M. Wetzels, "A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation, " BMC Nephrology, vol. 14, article 47, 2013.
28. R. Y. Gohh, A. F. Yango, P. E. Morrissey et al., "Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients, " American Journal of Transplantation, vol. 5, no. 12, pp. 2907-2912, 2005.
29. V. J. Savin, R. Sharma, M. Sharma et al., "Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis, " The New England Journal of Medicine, vol. 334, no. 14, pp. 878-883, 1996.
30. M. Sharma, R. Sharma, E. T. Mccarthy, and V. J. Savin, "'The FSGS factor:' enrichment and in vivo effect of activity fromfocal segmental glomerulosclerosis plasma, " Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 552-561, 1999.
31. G. Candiano, L. Musante, M. Carraro et al., "Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis, " Journal of the American Society of Nephrology, vol. 12, no. 1, pp. 143-150, 2001.
32. R. Sharma, M. Sharma, E. T. McCarthy, X.-L. Ge, and V. J. Savin, "Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro, " Kidney International, vol. 58, no. 5, pp. 1973-1979, 2000.
33. V. J. Savin, E. T. McCarthy, R. Sharma, D. Charba, and M. Sharma, "Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity, " Translational Research, vol. 151, no. 6, pp. 288-292, 2008.
34. K. Sgambat, M. Banks, and A. Moudgil, "Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome, " Pediatric Nephrology, vol. 28, no. 11, pp. 2131-2135, 2013.
35. M. J. Kemper, G. Wolf, and D. E. Müller-Wiefel, "Transmission of glomerular permeability factor from a mother to her child, " The New England Journal of Medicine, vol. 344, no. 5, pp. 386-387, 2001.
36. J. J. Harris, H. J. McCarthy, L. Ni et al., "Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1, " Journal of Pathology, vol. 229, no. 5, pp. 660-671, 2013.
37. D. S. Charba, R. C. Wiggins, M. Goyal et al., "Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (Palb), " American Journal of Physiology-Renal Physiology, vol. 297, no. 1, pp. F138-F144, 2009.
38. M. Thunø, B. MacHo, and J. Eugen-Olsen, "suPAR: the molecular crystal ball, " Disease Markers, vol. 27, no. 3-4, pp. 157-172, 2009.
39. A. L. Roldan, M. V. Cubellis, M. T. Masucci et al., "Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis, " The EMBO Journal, vol. 9, no. 2, pp. 467-474, 1990.
40. T. Plesner, N. Behrendt, and M. Ploug, "Structure, function and expression on blood and bone marrow cells of the urokinasetype plasminogen activator receptor, uPAR, " Stem Cells, vol. 15, no. 6, pp. 398-408, 1997.
41. G. Al-Atrash, S. Shetty, S. Idell et al., "IL-2-mediated upregulation of uPA and uPAR in natural killer cells, " Biochemical and Biophysical Research Communications, vol. 292, no. 1, pp. 184-189, 2002.
42. A. Nykjær, B. Møller, R. F. Todd III et al., "Urokinase receptor: an activation antigen in human T lymphocytes, " Journal of Immunology, vol. 152, no. 2, pp. 505-516, 1994.
43. T. Chavakis, A. K. Willuweit, F. Lupu, K. T. Preissner, and S. M. Kanse, "Release of soluble urokinase receptor from vascular cells, "Thrombosis and Haemostasis, vol. 86, no. 2, pp. 689-693, 2001.
44. H. W. Smith and C. J. Marshall, "Regulation of cell signalling by uPAR, " Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 23-36, 2010.
45. C. Wei, C. C. Möller, M. M. Altintas et al., "Modification of kidney barrier function by the urokinase receptor, " Nature Medicine, vol. 14, no. 1, pp. 55-63, 2008.
46. M. Ploug, E. Rønne, N. Behrendt, A. L. Jensen, F. Blasi, and K. Danø, "Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol, "The Journal of Biological Chemistry, vol. 266, no. 3, pp. 1926-1933, 1991.
47. N. Behrendt, M. Ploug, L. Patthy, G. Houen, F. Blasi, and K. Danø, "The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator, " The Journal of Biological Chemistry, vol. 266, no. 12, pp. 7842-7847, 1991.
48. C. Østergaard, T. Benfield, J. D. Lundgren, and J. Eugen-Olsen, "Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome, " Scandinavian Journal of Infectious Diseases, vol. 36, no. 1, pp. 14-19, 2004.
49. A. Gustafsson, V. Ajeti, and L. Ljunggren, "Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels, " Biomarker Insights, vol. 6, pp. 119-125, 2011.
50. N. Sidenius, C. F. M. Sier, and F. Blasi, "Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo, " FEBS Letters, vol. 475, no. 1, pp. 52-56, 2000.
51. J. Eugen-Olsen, O. Andersen, A. Linneberg et al., "Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes andmortality in the general population, " Journal of Internal Medicine, vol. 268, no. 3, pp. 296-308, 2010.
52. M. Persson, G. Engström, H. Björkbacka, and B. Hedblad, "Soluble urokinase plasminogen activator receptor in plasma is associated with incidence ofCVD. Results fromtheMalmöDiet and Cancer Study, " Atherosclerosis, vol. 220, no. 2, pp. 502-505, 2012.
53. K. Donadello, S. Scolletta, C. Covajes, and J.-L. Vincent, "suPAR as a prognostic biomarker in sepsis, " BMC Medicine, vol. 10, article 2, 2012.
54. T. H. Haupt, J. Petersen, G. Ellekilde et al., "Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study, " Critical Care, vol. 16, no. 4, article R130, 2012.
55. B. Meijers, R. Poesen, K. Claes et al., "Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease, " Kidney International, vol. 87, no. 1, pp. 210-216, 2015.
56. G. I. Welsh and M. A. Saleem, "The podocyte cytoskeletonkey to a functioning glomerulus in health and disease, " Nature Reviews Nephrology, vol. 8, no. 1, pp. 14-21, 2012.
57. B. Zhang, W. Shi, J. Ma et al., "The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury, " Journal ofMolecularMedicine, vol. 90, no. 12, pp. 1407-1420, 2012.
58. M.-J. Wu, C.-H. Chang, K.-H. Shu, H.-C. Ho, J.-R. Li, and Y.-C. Fu, "Rapamycin promotes podocyte migration through the upregulation of urokinase receptor, " Transplantation Proceedings, vol. 46, no. 4, pp. 1226-1228, 2014.
59. J. Ma, B. Zhang, S. Liu et al., "1, 25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria, " PLoS ONE, vol. 8, no. 5, Article ID e64912, 2013.
60. B. Zhang, S. Xie, W. Shi, and Y. Yang, "Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria, "Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1746-1755, 2012.
61. C.-C. Cheng, Y.-F. Lee, J.-L. Lan et al., "Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model, " Lupus, vol. 22, no. 6, pp. 554-561, 2013.
62. A. Fornoni, J. Sageshima, C. Wei et al., "Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis, " Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011.
63. D. L. Veron, G. Villegas, P. K. Aggarwal et al., "Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphavbeta3 integrin signaling in the glomerulus, " PLoS ONE, vol. 7, no. 7, Article ID e40589, 2012.
64. M. J. Kemper, C. Wei, and J. Reiser, "Transmissionof glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child, " American Journal of Kidney Diseases, vol. 61, no. 2, p. 352, 2013.
65. N. Alachkar, C. Wei, L. J. Arend et al., "Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy, " Transplantation, vol. 96, no. 7, pp. 649-656, 2013.
66. C. Morath, C. Wei, S. Macher-Goeppinger, V. Schwenger, M. Zeier, and J. Reiser, "Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification, " American Journal of Therapeutics, vol. 20, no. 2, pp. 226-229, 2013.
67. J. Huang, G. Liu, Y.-M. Zhang et al., "Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis, " BMC Medicine, vol. 12, article 81, 2014.
68. D. Cathelin, S. Placier, M. Ploug et al., "Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice, " Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1662-1668, 2014.
69. R. J. H. Maas, J. F. M. Wetzels, and J. K. J. Deegens, "Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease, " Kidney International, vol. 85, no. 3, p. 711, 2014.
70. T. Kitao, T. Kimata, E. Kanda et al., "Soluble urokinase receptor in a toddler with focal segmental glomerulosclerosis, " Kidney International, vol. 86, no. 1, p. 208, 2014.
71. E. Drucker and K. Krapfenbauer, "Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine, " EPMA Journal, vol. 4, article 7, 2013.
72. J. P. A. Ioannidis, D. B. Allison, C. A. Ball et al., "Repeatability of published microarray gene expression analyses, " Nature Genetics, vol. 41, no. 2, pp. 149-155, 2009.
73. E. vonElm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, " Annals of Internal Medicine, vol. 147, no. 8, pp. 573-577, 2007.
74. C. Kilkenny, W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, "Improving bioscience research reporting: the arrive guidelines for reporting animal research, " PLoS Biology, vol. 8, no. 6, Article ID e1000412, 2010.
75. R. J. H. Maas, J. K. J. Deegens, and J. F. M. Wetzels, "Serum suPAR in patients with FSGS: trash or treasure?" Pediatric Nephrology, vol. 28, no. 7, pp. 1041-1048, 2013.
76. O. Slot, N. Brünner, H. Locht, P. Oxholm, and R. W. Stephens, "Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 58, no. 8, pp. 488-492, 1999.
77. J. A. Jefferson and C. E. Alpers, "Glomerular disease: 'suPAR'-exciting times for FSGS, " Nature Reviews Nephrology, vol. 9, no. 3, pp. 127-128, 2013.
78. T.-H. Yoo, C. E. Pedigo, J. Guzman et al., "Sphingomyelinaselike phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease, " Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 133-147, 2015.
79. H. Trachtman, C. Wei, and J. Reiser, "Circulating factor in FSGS: a black sheep in the suPAR family?" Pediatric Nephrology, vol. 28, no. 7, pp. 1151-1152, 2013.
80. D. Schlöndorff, "Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS, " Kidney International, vol. 85, no. 3, pp. 499-501, 2014.
81. S. Sever, H. Trachtman, C. Wei, and J. Reiser, "Is there clinical value in measuring suPAR levels in FSGS?" Clinical Journal of the American Society of Nephrology, vol. 8, no. 8, pp. 1273-1275, 2013.
82. R. Riisbro, I. J. Christensen, C. Høgdall, N. Brünner, and E. Høgdall, "Soluble urokinase plasminogen activator receptor measurements: influence of sample handling, " International Journal of Biological Markers, vol. 16, no. 4, pp. 233-239, 2001.
83. A. E. Schutte, A. Myburgh, M. H. Olsen, J. Eugen-Olsen, and R. Schutte, "Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study, " Thrombosis Research, vol. 130, no. 2, pp. 273-277, 2012.
84. B. Meijers and B. Sprangers, "The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?" Clinical Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 1835-1836, 2014.
85. L. Shen, G. Lu, N. Dong, L. Jiang, Z. Ma, and C. Ruan, "Von willebrand factor, ADAMTS13 activity, TNF-and their relationships in patients with chronic kidney disease, " Experimental andTherapeutic Medicine, vol. 3, no. 3, pp. 530-534, 2012.
86. T. Takamatsu, N. Yasuda, T. Ohno, T. Kanoh, H. Uchino, and A. Fujisawa, "Soluble interleukin-2 receptors in the serum of patients with chronic renal failure, " Tohoku Journal of Experimental Medicine, vol. 155, no. 4, pp. 343-347, 1988.
87. R. J. Caruana, M. S. Leffell, S. A. Lobel, H. T. Campbell, and P. L. Cheek, "Chronic T-lymphocyte activation in chronic renal failure: a study of hemodialysis, CAPD and pre-dialysis patients, " International Journal of Artificial Organs, vol. 15, no. 2, pp. 93-98, 1992.
88. G. Almroth, J. Lönn, F. Uhlin et al., "Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity Creactive protein and soluble urokinase plasminogen activator receptor. inflammation markers in chronic haemodialysis patients?" Scandinavian Journal of Immunology, vol. 78, no. 3, pp. 285-290, 2013.
89. A. Segarra, E. Jatem, M. T. Quiles et al., "Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis, " Nefrologia, vol. 34, no. 1, pp. 53-61, 2014.
90. T. C. Jungraithmayr, K. Hofer, P. Cochat et al., "Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation, " Journal of the American Society of Nephrology, vol. 22, no. 3, pp. 579-585, 2011.
91. A. Vasudevan, A. Siji, A. Raghavendra, T. S. Sridhar, and K. D. Phadke, "NPHS2 mutations in Indian children with sporadic early steroid resistant nephrotic syndrome, " Indian Pediatrics, vol. 49, no. 3, pp. 231-233, 2012.
92. S. Weber and B. Tönshoff, "Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects, " Transplantation, vol. 80, supplement 1, pp. S128-S134, 2005.
93. R. Bertelli, F. Ginevri, G. Caridi et al., "Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin, " American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1314-1321, 2003.
94. J. Gellermann, F. Schaefer, and U. Querfeld, "Serum suPAR levels aremodulated byimmunosuppressive therapy of minimal change nephrotic syndrome, " Pediatric Nephrology, vol. 29, no. 12, pp. 2411-2414, 2014.
95. O. Andersen, J. Eugen-Olsen, K. Kofoed, J. Iversen, and S. B. Haugaard, "Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy, " Journal ofMedicalVirology, vol. 80, no. 2, pp. 209-216, 2008.
96. S. R. Ostrowski, T. L. Katzenstein, M. Pedersen et al., "Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy, " Scandinavian Journal of Immunology, vol. 63, no. 6, pp. 478-486, 2006.
97. S. J. Park, M. A. Saleem, and J. I. Shin, "Elevated soluble urokinase receptors in focal segmental glomerulosclerosis: a role for IL-2?" Kidney International, vol. 85, no. 6, pp. 1469-1470, 2014.
98. P. F. Piguet, C. Vesin, Y. Donati, F. Tacchini-Cottier, D. Belin, and C. Barazzone, "Urokinase receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice, " Circulation, vol. 99, no. 25, pp. 3315-3321, 1999.
99. M. Delville, T. K. Sigdel, C. Wei et al., "A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation, " Science Translational Medicine, vol. 6, no. 256, Article ID 256ra136, 2014.
100. S. Shishido, H. Satou, M. Muramatsu et al., "Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation, " Clinical Transplantation, vol. 27, no. 2, pp. E143-E150, 2013.
101. M. Bitzan, S. Babayeva, A. Vasudevan, P. Goodyer, and E. Torban, "TNF pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and 3 integrin activation, " Pediatric Nephrology, vol. 27, no. 12, pp. 2217-2226, 2012.
102. M. A. Saleem, "The phenomenon of focal segmental glomerulosclerosis post-transplantation-a one-hit wonder?" Pediatric Nephrology, vol. 27, no. 12, pp. 2163-2166, 2012.
103. C. Faul, M. Donnelly, S. Merscher-Gomez et al., "The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A, " Nature Medicine, vol. 14, no. 9, pp. 931-938, 2008.
104. A. Kronbichler and A. Bruchfeld, "Rituximab in adult minimal change disease and focal segmental glomerulosclerosis, " Nephron-Clinical Practice, vol. 128, no. 3-4, pp. 277-282, 2014.
105. A. Kronbichler, J. Kerschbaum, G. Fernandez-Fresnedo et al., "Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review, " American Journal of Nephrology, vol. 39, no. 4, pp. 322-330, 2014.
106. J. I. Shin and A. Kronbichler, "Rituximab for patients with nephrotic syndrome, " The Lancet, vol. 385, no. 9964, pp. 225-226, 2015.